<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations in MECP2, encoding <z:chebi fb="36" ids="29309">methyl</z:chebi> CpG binding protein 2 (MeCP2), cause most cases of <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e>), an <z:hpo ids='HP_0001417'>X-linked</z:hpo> <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorder</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e> and <z:hpo ids='HP_0000717'>autism</z:hpo> are "<z:hpo ids='HP_0000729'>pervasive developmental disorders</z:hpo>" and share a loss of social, cognitive and language skills and a gain in repetitive <z:hpo ids='HP_0000733'>stereotyped behavior</z:hpo>, following apparently <z:mpath ids='MPATH_458'>normal</z:mpath> perinatal development </plain></SENT>
<SENT sid="2" pm="."><plain>Although MECP2 coding mutations are a rare cause of <z:hpo ids='HP_0000717'>autism</z:hpo>, MeCP2 expression defects were previously found in <z:hpo ids='HP_0000717'>autism</z:hpo> brain </plain></SENT>
<SENT sid="3" pm="."><plain>To further study the role of MeCP2 in <z:hpo ids='HP_0000729'>autism spectrum disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASDs</z:e>), we determined the frequency of MeCP2 expression defects in brain samples from <z:hpo ids='HP_0000717'>autism</z:hpo> and other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASDs</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We also tested the hypotheses that MECP2 promoter mutations or aberrant promoter methylation correlate with reduced expression in cases of idiopathic <z:hpo ids='HP_0000717'>autism</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>MeCP2 immunofluorescence in <z:hpo ids='HP_0000717'>autism</z:hpo> and other <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorders</z:e> was quantified by laser scanning cytometry and compared with control postmortem cerebral cortex samples on a large tissue microarray </plain></SENT>
<SENT sid="6" pm="."><plain>A significant reduction in MeCP2 expression compared to age-matched controls was found in 11/14 <z:hpo ids='HP_0000717'>autism</z:hpo> (79%), 9/9 RTT (100%), 4/4 Angelman syndrome (100%), 3/4 Prader-Willi syndrome (75%), 3/5 Down syndrome (60%), and 2/2 <z:hpo ids='HP_0007018'>attention deficit hyperactivity disorder</z:hpo> (100%) frontal cortex samples </plain></SENT>
<SENT sid="7" pm="."><plain>One <z:hpo ids='HP_0000717'>autism</z:hpo> female was heterozygous for a rare MECP2 promoter variant that correlated with reduced MeCP2 expression </plain></SENT>
<SENT sid="8" pm="."><plain>A more frequent occurrence was significantly increased MECP2 promoter methylation in <z:hpo ids='HP_0000717'>autism</z:hpo> male frontal cortex compared to controls </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, percent promoter methylation of MECP2 significantly correlated with reduced MeCP2 protein expression </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that both genetic and epigenetic defects lead to reduced MeCP2 expression and may be important in the complex etiology of <z:hpo ids='HP_0000717'>autism</z:hpo> </plain></SENT>
</text></document>